BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomed Pharmacother 2017;88:635-43. [PMID: 28142120 DOI: 10.1016/j.biopha.2017.01.071] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Amantino CF, de Baptista-Neto Á, Badino AC, Siqueira-Moura MP, Tedesco AC, Primo FL. Anthraquinone encapsulation into polymeric nanocapsules as a new drug from biotechnological origin designed for photodynamic therapy. Photodiagnosis Photodyn Ther 2020;31:101815. [PMID: 32407889 DOI: 10.1016/j.pdpdt.2020.101815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
2 Demirbolat GM, Altintas L, Yilmaz S, Arsoy T, Sözmen M, Degim IT. Nanodesigning of multifunctional quantum dots and nanoparticles for the treatment of fibrosarcoma. J Microencapsul 2021;:1-40. [PMID: 34796787 DOI: 10.1080/02652048.2021.1990423] [Reference Citation Analysis]
3 Demirtürk N, Bilensoy E. Nanocarriers targeting the diseases of the pancreas. Eur J Pharm Biopharm 2021:S0939-6411(21)00337-4. [PMID: 34852262 DOI: 10.1016/j.ejpb.2021.11.006] [Reference Citation Analysis]
4 Gillson J, Ramaswamy Y, Singh G, Gorfe AA, Pavlakis N, Samra J, Mittal A, Sahni S. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Cancers (Basel). 2020;12. [PMID: 32456277 DOI: 10.3390/cancers12051341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
5 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Mahajan S, Patharkar A, Kuche K, Maheshwari R, Deb PK, Kalia K, Tekade RK. Functionalized carbon nanotubes as emerging delivery system for the treatment of cancer. Int J Pharm 2018;548:540-58. [PMID: 29997043 DOI: 10.1016/j.ijpharm.2018.07.027] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 17.0] [Reference Citation Analysis]
7 Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M. RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine. Int J Nanomedicine 2019;14:7263-79. [PMID: 31686807 DOI: 10.2147/IJN.S212978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
8 Lafuente-Gómez N, Milán-Rois P, García-Soriano D, Luengo Y, Cordani M, Alarcón-Iniesta H, Salas G, Somoza Á. Smart Modification on Magnetic Nanoparticles Dramatically Enhances Their Therapeutic Properties. Cancers (Basel) 2021;13:4095. [PMID: 34439250 DOI: 10.3390/cancers13164095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jang SI, Fang S, Baek YY, Lee DH, Na K, Lee SY, Lee DK. Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation. Int J Mol Sci 2020;21:E1605. [PMID: 32111094 DOI: 10.3390/ijms21051605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Park JY, Cho YL, Chae JR, Moon SH, Cho WG, Choi YJ, Lee SJ, Kang WJ. Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer. Mol Ther Nucleic Acids 2018;12:543-53. [PMID: 30195790 DOI: 10.1016/j.omtn.2018.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
11 Pascual-Serra R, Fernández-Aroca DM, Sabater S, Roche O, Andrés I, Ortega-Muelas M, Arconada-Luque E, Garcia-Flores N, Bossi G, Belandia B, Ruiz-Hidalgo MJ, Sánchez-Prieto R. p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models. Radiother Oncol 2021;156:136-44. [PMID: 33310004 DOI: 10.1016/j.radonc.2020.12.008] [Reference Citation Analysis]
12 Vatanparast M, Shariatinia Z. Revealing the role of different nitrogen functionalities in the drug delivery performance of graphene quantum dots: a combined density functional theory and molecular dynamics approach. J Mater Chem B 2019;7:6156-71. [DOI: 10.1039/c9tb00971j] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 8.7] [Reference Citation Analysis]
13 Habib S, Singh M. Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine-Combination Therapy. Nanomaterials (Basel) 2021;11:597. [PMID: 33673636 DOI: 10.3390/nano11030597] [Reference Citation Analysis]
14 Xue R, Meng Q, Lu D, Liu X, Wang Y, Hao J. Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway. Oxid Med Cell Longev 2018;2018:2798070. [PMID: 30046371 DOI: 10.1155/2018/2798070] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
15 Li Y, Wu J, Wang J, Hu X, Cai J, Xiang D. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. Acta Biomaterialia 2020;101:519-30. [DOI: 10.1016/j.actbio.2019.10.022] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 22.5] [Reference Citation Analysis]
16 Burks J, Nadella S, Mahmud A, Mankongpaisarnrung C, Wang J, Hahm JI, Tucker RD, Shivapurkar N, Stern ST, Smith JP. Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. Cell Mol Gastroenterol Hepatol 2018;6:17-32. [PMID: 29928669 DOI: 10.1016/j.jcmgh.2018.02.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
17 Cong M, Xu G, Yang S, Zhang J, Zhang W, Dhumal D, Laurini E, Zhang K, Xia Y, Pricl S, Peng L, Zhao W. A self-assembling prodrug nanosystem to enhance metabolic stability and anticancer activity of gemcitabine. Chinese Chemical Letters 2021. [DOI: 10.1016/j.cclet.2021.11.083] [Reference Citation Analysis]
18 Greene MK, Johnston MC, Scott CJ. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers (Basel) 2021;13:6175. [PMID: 34944794 DOI: 10.3390/cancers13246175] [Reference Citation Analysis]
19 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Ahmad R, Srivastava S, Ghosh S, Khare SK. Phytochemical delivery through nanocarriers: a review. Colloids Surf B Biointerfaces 2021;197:111389. [PMID: 33075659 DOI: 10.1016/j.colsurfb.2020.111389] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
21 Fan F, Jin L, Yang L. pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer. ACS Appl Mater Interfaces 2021;13:12824-35. [PMID: 33689289 DOI: 10.1021/acsami.0c16576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang H, Sun G, Zhang Z, Ou Y. Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy. Biomed Pharmacother 2017;91:241-50. [PMID: 28460227 DOI: 10.1016/j.biopha.2017.04.104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
23 Banstola A, Pham TT, Jeong JH, Yook S. Polydopamine-tailored paclitaxel-loaded polymeric microspheres with adhered NIR-controllable gold nanoparticles for chemo-phototherapy of pancreatic cancer. Drug Deliv. 2019;26:629-640. [PMID: 31237149 DOI: 10.1080/10717544.2019.1628118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
24 Zhang H, Wang K, Na K, Li D, Li Z, Zhao D, Zhong L, Wang M, Kou L, Luo C, Zhang H, Kan Q, Ding H, He Z, Sun J. Striking a Balance between Carbonate/Carbamate Linkage Bond- and Reduction-Sensitive Disulfide Bond-Bearing Linker for Tailored Controlled Release: In Situ Covalent-Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation. J Med Chem 2018;61:4904-17. [DOI: 10.1021/acs.jmedchem.8b00293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
25 Sielaff CM, Mousa SA. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J Cancer Res Clin Oncol 2018;144:1205-17. [PMID: 29721665 DOI: 10.1007/s00432-018-2651-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
26 Rebelo A, Reis C. Emerging therapeutic nanotechnologies in pancreatic cancer: advances, risks and challenges. Ther Deliv 2018;9:691-4. [PMID: 30277137 DOI: 10.4155/tde-2018-0048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lisitskiy VA, Khan H, Popova TV, Chubarov AS, Zakharova OD, Akulov AE, Shevelev OB, Zavjalov EL, Koptyug IV, Moshkin MP, Silnikov VN, Ahmad S, Godovikova TS. Multifunctional human serum albumin-therapeutic nucleotide conjugate with redox and pH-sensitive drug release mechanism for cancer theranostics. Bioorg Med Chem Lett 2017;27:3925-30. [PMID: 28676274 DOI: 10.1016/j.bmcl.2017.05.084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
28 Zhang X, Zhang J, Liu W, Wang Y, Wu J, Zhao S, Zhao M, Peng S. Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway. Sci Rep 2020;10:15729. [PMID: 32978501 DOI: 10.1038/s41598-020-72824-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Banstola A, Emami F, Jeong J, Yook S. Current Applications of Gold Nanoparticles for Medical Imaging and as Treatment Agents for Managing Pancreatic Cancer. Macromol Res 2018;26:955-64. [DOI: 10.1007/s13233-018-6139-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
30 Glenn JD, Xue P, Whartenby KA. Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis. J Neuroimmunol 2018;316:7-16. [PMID: 29274729 DOI: 10.1016/j.jneuroim.2017.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 David KI, Ravikumar TS, Sethuraman S, Krishnan UM. Development and evaluation of a multi-functional organic-inorganic nanotheranostic hybrid for pancreatic cancer therapy. Biomed Mater 2021;16. [PMID: 34298521 DOI: 10.1088/1748-605X/ac177c] [Reference Citation Analysis]
32 Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen Q, Zhang Y, Lu Y, Ding X, Jiang C. Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B 2020;10:1563-75. [PMID: 32963950 DOI: 10.1016/j.apsb.2019.11.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]